Skip to main content

Investigating the potential of polysaccharides, probiotics based Fisetin loaded self-nanoemulsifying drug delivery system in alleviating influenza infection in chronic obstructive pulmonary disease

Start year: 2024

Summary: Chronic Obstructive Pulmonary Disease (COPD) is the second most common cause of hospitalisation and the fifth commonest cause of death in Australia. Influenza A virus (IAV) infection is particularly prevalent and life-threatening in COPD patients causing tremendous healthcare and economic burdens worldwide. IAV impacts the global population through seasonal outbreaks and frequent but unpredictable pandemics. Current treatments have limited efficacy and are complicated by a high frequency of mutations in IAVs, thereby creating an urgent need for more effective therapies. Fisetin is a phytoconstituents with anti-inflammatory and anti-viral properties, but it has poor oral bioavailability and limited gastrointestinal absorption. Thus, formulating Fistein into engineered nanoparticles could be a potential approach to achieve increased uptake by cells and improve efficacy at low doses for a range of diseases including IAV infection in COPD. We hypothesise that encapsulating Fisetin in engineered nanoparticulate system will reduce IAV-induced inflammation in healthy people and COPD patients. We aim to develop Fisetin-loaded self-nanoemulsifying drug delivery systems/nanoparticles to deliver Fisetin as an effective therapeutic intervention for IAV infection in healthy people and those with COPD.